Home › Trials › NCT05691608

Molecular profiling for treating pediatric and young adult cancers

MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2

Not applicable Interventional Gustave Roussy, Cancer Campus, Grand Paris · NCT05691608

This study is testing if using genetic information from tumors can help doctors find better treatments for kids and young adults with hard-to-treat cancers.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment1800 (estimated)
Ages6 Years to 25 Years
SexAll
SponsorGustave Roussy, Cancer Campus, Grand Paris Academic / other
Locations29 sites (Paris, Villejuif and 28 other locations)
Trial IDNCT05691608 on ClinicalTrials.gov

What this trial studies

MAPPYACTS 2 is an international multicentric clinical initiative aimed at providing tailored therapeutic recommendations based on the molecular characteristics of tumors in pediatric and young adult patients with relapsed or refractory malignancies. The study utilizes advanced genomic techniques, including Whole Exome Sequencing and RNA Sequencing, to identify genomic alterations that may inform targeted treatment options. It also aims to create a comprehensive clinical database to track treatment outcomes and enhance patient care through collaboration among biologists, scientists, and physicians. The program will link to interventional studies and ancillary research to foster the development of new treatment strategies.

Who should consider this trial

Good fit: Ideal candidates include pediatric and young adult patients with relapsed or refractory solid tumors or leukemia who are eligible for molecular profiling and potential experimental treatments.

Not a fit: Patients with tumors that are not relapsed or refractory to standard treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for children and young adults with difficult-to-treat cancers.

How similar studies have performed: Previous studies utilizing molecular profiling for cancer treatment have shown promise, indicating that this approach is building on established methodologies.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient referred for sequencing of the tumor within the FMG2025 or equivalent program and written informed consent for FMG2025 "Cancers et leucémies pédiatriques en échec de traitement" or equivalent, according to local regulations
* Written informed consent of MAPPYACTS 2 to collect molecular and comprehensive clinical data on cancer diagnosis, therapies, therapy outcomes, to provide clinical therapeutic recommendations, to collect follow-up data on treatment and patients' outcome; optional written consents to perform to ancillary research studies, according to local regulations. The written consent will include access to reimbursement data from the French national health insurance through linkage with the Système National des Données de Santé (SNDS) or equivalent.
* Patient with histologically/cytologically confirmed solid tumor or leukemia which is relapsed or refractory to standard treatment and who is potentially eligible for an experimental treatment or an early phase clinical trial
* Planned tumor biopsy, surgical resection, bone marrow or blood sample or recently (preferably within the last 3 months) archived frozen tumor material available of the current recurrent or refractory disease
* Patients aged ≤ 25 years at the time of initial diagnosis
* Performance status and life expectancy \> 3 months expected to allow enrolment into an clinical trial
* Patients affiliated with a Social Security Regimen or beneficiary of the same, as per local regulatory requirements

Exclusion Criteria:

* Any concurrent illness or laboratory abnormality that, in the opinion of the investigator, is likely to interfere with the interpretation of study results
* Pregnant women

Where this trial is running

Paris, Villejuif and 28 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Solid TumorLeukemia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.